ALK+ Anaplastic Large Cell Lymphoma Clinical Trial
Official title:
A "Window of Opportunity" Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
| Verified date | February 2022 |
| Source | Arbeitsgemeinschaft medikamentoese Tumortherapie |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This is an open label pilot study of combining BV in a licensed indication with imatinib in patients with ALCL. It is intended as a "window of opportunity" trial in which the study drugs will be given as an initial substitute for conventional chemotherapy with the intention to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell transplantation, if eligible.
| Status | Terminated |
| Enrollment | 3 |
| Est. completion date | November 3, 2021 |
| Est. primary completion date | November 3, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients = 18 years of age - ALK+ ALCL - Histologically confirmed relapse after having achieved a PR or CR with conventional therapy - Refractoriness to conventional chemotherapy (SD or PD after conventional chemotherapy) - Not able to receive conventional chemotherapy (e.g. due to comorbidities) - Adequate organ function, defined as the following: - Absolute neutrophil count = 1,500/µL unless there is known hematologic/solid tumor marrow involvement - Platelet count = 75,000/ µL unless there is known marrow involvement of the disease - Total bilirubin must be < 1.5 x the upper limit of the normal (ULN) unless the elevation is known to be due to Gilbert syndrome. - ALT or AST must be < 3 x the upper limit of the normal range. AST and ALT may be elevated up to 5 times the ULN if their elevation can be reasonably ascribed to the presence of hematologic/solid tumor in liver. - Serum creatinine must be < 2.0 mg/dL and/or creatinine clearance or calculated creatinine clearance > 40 mL/minute. - Hemoglobin must be = 8g/dL. - Written, voluntarily signed informed consent - Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, must practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent until 6 months after the last doses of BV and until last doses of imatinib, whatever occurs later, or agrees to completely abstain from heterosexual intercourse. - Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of BV, or agrees to completely abstain from heterosexual intercourse. Exclusion Criteria: - Patient has received any other investigational treatment within 28 days before study entry - Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin or imatinib - ECOG performance status = 3 - Acute or chronic infections - Female patients who are pregnant or breast-feeding - Known diagnosis of HIV - Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection - Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to the protocol. - Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of PML - Symptomatic neurologic disease compromising normal activities of daily living or requiring medications - Any sensory or motor peripheral neuropathy greater than or equal to Grade 2 - Known history of any of the following cardiovascular conditions - Myocardial infarction within 2 years of study entry - New York Heart Association (NYHA) Class III or IV heart failure - Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities - Recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50% - Any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose - Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection. |
| Country | Name | City | State |
|---|---|---|---|
| Austria | Universitätsklinik f. Innere Medizin I, AKH Wien, Klinische Abteilung für Hämatologie und Hämostaseologie | Wien |
| Lead Sponsor | Collaborator |
|---|---|
| Arbeitsgemeinschaft medikamentoese Tumortherapie |
Austria,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Safety of brentuximab vedotin and imatinib regime as measured by type, frequency and severity of adverse events (AEs) and their relationship to study treatment | up to 6 years | ||
| Secondary | Efficacy of brentuximab vedotin and imatinib regime as measured by proportion of patients responding to treatment | up to 6 years | ||
| Secondary | Ability to receive further Treatment as measured by number of patients being able to receive transplantation | up to 6 years | ||
| Secondary | Progression-free survival as measured by proportion of patients displaying progressive disease | up to 6 years | ||
| Secondary | Overall survival as measured by documentation of deaths | up to 6 years |